- Q1 2024 Calliditas Therapeutics AB Earnings Call TranscriptMay 23, 2024kr122.2 (+7.19%)Earnings
- Q4 2023 Calliditas Therapeutics AB Earnings Call TranscriptFeb 21, 2024kr108.3 (+1.31%)Earnings
- Q3 2023 Calliditas Therapeutics AB Earnings Call TranscriptNov 07, 2023kr87.6 (-5.40%)Earnings
- Q2 2023 Calliditas Therapeutics AB Earnings Call TranscriptAug 17, 2023kr86.25 (-13.92%)Earnings
- Q1 2023 Calliditas Therapeutics AB Earnings Call TranscriptMay 16, 2023kr107.2 (-18.42%)Earnings
- Calliditas Therapeutics AB Nefigard Topline Data Presentation TranscriptMar 13, 2023
- Q4 2022 Calliditas Therapeutics AB Earnings Call TranscriptFeb 23, 2023kr107 (+16.49%)Earnings
- Calliditas Therapeutics AB Fireside Chat with Everest Medicines Ltd TranscriptDec 14, 2022
- Q3 2022 Calliditas Therapeutics AB Earnings Call TranscriptNov 14, 2022kr78.9 (+0.96%)Earnings
- Calliditas Therapeutics AB KOL Webinar TranscriptNov 08, 2022
- Q2 2022 Calliditas Therapeutics AB Earnings Call TranscriptAug 18, 2022kr91.8 (-15.55%)Earnings
- Q1 2022 Calliditas Therapeutics AB Earnings Call TranscriptMay 18, 2022kr79.6 (+7.49%)Earnings
- Q4 2021 Calliditas Therapeutics AB Earnings Call TranscriptFeb 24, 2022kr81.3 (-6.12%)Earnings
- Calliditas Therapeutics AB -FDA Approval of TARPEYO to Reduce Proteinuria in IgA Nephropathy TranscriptDec 16, 2021
- Q3 2021 Calliditas Therapeutics AB Earnings Call TranscriptNov 18, 2021kr80 (+8.25%)Earnings
- Q2 2021 Calliditas Therapeutics AB Earnings Call TranscriptAug 19, 2021kr96.5 (-1.63%)Earnings
- Q1 2021 Calliditas Therapeutics AB Earnings Call TranscriptMay 18, 2021kr120.8 (+0.50%)Earnings
- Calliditas Therapeutics AB (publ) - Special Call TranscriptMar 10, 2021
- Q4 2020 Calliditas Therapeutics AB Earnings Call TranscriptFeb 18, 2021kr128.6 (-3.02%)Earnings
- Calliditas Therapeutics AB Corporate Analyst Meeting TranscriptJan 20, 2021
- Q3 2020 Calliditas Therapeutics AB Earnings Call TranscriptNov 12, 2020kr145.8 (-4.58%)Earnings
- Calliditas Therapeutics AB (publ) - Special Call TranscriptNov 09, 2020
- Q2 2020 Calliditas Therapeutics AB Earnings Call TranscriptAug 13, 2020kr103 (+2.39%)Earnings
- Q1 2020 Calliditas Therapeutics AB Earnings Call TranscriptMay 14, 2020kr92.5 (-9.49%)Earnings
Q4 2023 Calliditas Therapeutics AB Earnings Call Transcript
©- -
Thank you very much, and welcome to the Q4 2023 presentation. I'd like to draw your attention, first of all, to the disclaimer notice as usual, which covers forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended. And I refer you to public filings, including those containing risk factors.
Next page, please. So with regards to Q4, and to start just with some highlights, so obviously the key event for this quarter was December 20, the FDA granted us full approval of TARPEYO based on the submission of the full Phase 3 data set, which we filed in June 2023.
The Phase 3 trial showed a highly statistically significant outcome on the primary endpoint of eGFR with a p-value of less than 0.0001. Additional supportive data obviously is being presented on conferences and in other place in terms of slope analysis, three mils per minute per year in favor of TARPEYO versus placebo, a statistically significant impact on microhematuria and biomarkers such
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)